[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338332-105":59,"doc-detail-338332-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","expression-of-c-erb-b2-oncoprotein-as-a-neoantigen-strategy-to-repurpose-anti-neu-antibody-therapy-in-a-model-of-melanoma","Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma","","Study tests repurposing a biomarker associated with breast cancer for melanoma by targeting HER2/neu-equivalent c-erb-B2. A lentivirus encoding rat c-erb-B2 is introduced into B16 melanoma cells and tumors to create B16/neu as a neoantigen target for anti-c-erb-B2 monoclonal antibody. Results show statistically significant in vivo anti-tumor activity mediated by NK-cell antibody-dependent cell-mediated cytotoxicity, including complete responses and long-term survival when combined treatment is used.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expression-of-c-erb-b2-oncoprotein-as-a-neoantigen-strategy-to-repurpose-anti-neu-antibody-therapy-in-a-model-of-melanoma/338332/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expression-of-c-erb-b2-oncoprotein-as-a-neoantigen-strategy-to-repurpose-anti-neu-antibody-therapy-in-a-model-of-melanoma/338332.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic strategy tested in this study?","Question",{"text":112,"@type":113},"The study evaluates a strategy that repurposes the c-erb-B2 oncoprotein as a neoantigen target for melanoma using anti-c-erb-B2 monoclonal antibody.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is c-erb-B2 introduced and used in the melanoma model?",{"text":117,"@type":113},"A lentivirus encoding rat c-erb-B2 is used to transfect B16 melanoma in vitro and inoculate tumors in vivo, generating c-erb-B2 expression as a neoantigen target.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune mechanism mediates the anti-tumor response?",{"text":121,"@type":113},"The anti-tumor effect is mediated by NK-cell antibody-dependent cell-mediated cytotoxicity (ADCC) triggered by antibody targeting.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338332,1790181934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nExpression of c-erb-B2 oncoprotein as a neoantigen strategy torepurpose anti-neu antibody therapy in a model of melanoma  \nEmmanuel M. Gabriel1􀀍, Brian Necela2, Deborah Bahr2, SnehaVivekanandhan2, Barath Shreeder2, Sanjay Bagaria1 & Keith L. Knutson2  \nIn this study, we tested a novel approach of“repurposing” a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2, an animal (rat) homolog to HER2/neu. This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of rat c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7.16.4). The c-erb-B2-expressing melanoma was designated  \nB16/neu. 7.16.4 produced statistically significant in vivo anti-tumor responses against B16/neu. This effect was mediated by NK-cell antibody-dependent cell-mediated cytotoxicity. To further model human melanoma (which expresses \u003C 5% HER2/neu), our c-erb-B2 encoding lentivirus was used to inoculate naïve (wild-type) B16 tumors in vivo, resulting in successful c-erb-B2 expression. When combined with 7.16.4, anti-tumor responses were again demonstrated where approximately 40% of mice treated with c-erb-B2 lentivirus and 7.16.4 achieved complete clinical response and long-term survival. For the first time, we demonstrated a novel strategy to repurpose c-erb-B2 as a neoantigen target for melanoma. Our findings are particularly significant in the contemporary setting where newer anti-HER2/neu antibody-drug therapies have shown increased efficacy.  \nAbbreviations  \nADC Antibody-drug conjugates  \nADCC Antibody-dependent cell-mediated cytotoxicity ANOVA Analysis of variance  \nFCS Fetal calf serum  \nIHC Immunohistochemistry KM Kaplan-Meier  \nIp Intraperitoneal  \nmm Millimeter  \nNK Natural killer  \nPBS Phosphate buffered saline  \npfu Plaque-forming units  \nRPMI Roswell Park Memorial Institute Medium  \nT-DM1 Ado-trastuzumab  \nT-DXd Trastuzumab deruxtecan  \nTTBS Tween Tris buffered saline  \nµg Microgram  \nµm Micrometer  \nµM Micromolar  \nSince the early 2010s, immune checkpoint blockade has vastly improved clinical outcomes for patients with locally advanced and metastatic melanoma1–3. However, up to 40–50% of these patients still die from melanoma or develop resistance to currently available immune checkpoint inhibitors4,5. While there are other targeted  \n1 Division of Surgical Oncology, Department of General Surgery, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. 2Department of Immunology, Mayo Clinic, Jacksonville, FL, USA. 􀀍 email: [Gabriel.Emmanuel@mayo.edu](Gabriel.Emmanuel@mayo.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nagents available for melanomas with BRAF mutations, durability of their response is limited6. Adverse events from immunotherapy or targeted therapies also limit their use, and there are populations of patients in whom immune checkpoint blockade is contraindicated, such as those with organ transplants7. Therefore, novel therapies and approaches are needed to continue to improve outcomes for melanoma patients and overcome emerging mechanisms of resistance.  \nFor melanoma and other cancers, there is much investigation into uncovering neoantigen biomarkers and an array of strategies to therapeutically target such neoantigens, including antigen-based vaccines and adoptive effector cell therapy (such as the recent approval of lifileucel, a personalized autologous tumor-infiltrating lymphocytes, or TIL, therapy)8–11. While the goal of these innovative approaches is to develop mainstream, clinically effective treatments, this may not be the case for many early therapeutics or may take decades to become realized through the industrial pipeli","cbCaiuNoYatgpF5a","https://ap.wps.com/l/cbCaiuNoYatgpF5a","pdf",2344788,13,"English","# Abstract\n## Strategy and rationale\n## Experimental approach\n## Results and significance\n## Abbreviations","[{\"question\":\"What is the main therapeutic strategy tested in this study?\",\"answer\":\"The study evaluates a strategy that repurposes the c-erb-B2 oncoprotein as a neoantigen target for melanoma using anti-c-erb-B2 monoclonal antibody.\"},{\"question\":\"How is c-erb-B2 introduced and used in the melanoma model?\",\"answer\":\"A lentivirus encoding rat c-erb-B2 is used to transfect B16 melanoma in vitro and inoculate tumors in vivo, generating c-erb-B2 expression as a neoantigen target.\"},{\"question\":\"What immune mechanism mediates the anti-tumor response?\",\"answer\":\"The anti-tumor effect is mediated by NK-cell antibody-dependent cell-mediated cytotoxicity (ADCC) triggered by antibody targeting.\"}]","Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma | PDF",1790023095,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaa4275de9db940364b4bddeb6dcc8a1.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa8622abfb98d42d6cf5d2c1903bb444.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/237c4a2c1c78f7e48e862a3e45154270.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ecc88a8b12d25ed4f6d0a918a97d723.webp",980,1287]